Bortezomib Completed Phase 2 Trials for Myelodysplastic Syndrome / Malignant Lymphomas / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01891968Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
NCT00511069Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia
NCT01323920Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
NCT00376961S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01029730Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
NCT00182637Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
NCT00093769Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00262860Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00217503Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
NCT00045695Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00066508Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy
NCT00740415Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
NCT00377052Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
NCT00513955Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT00428142Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00030875Bortezomib in Treating Patients With Mantle Cell Lymphoma